ERBB2 and breast carcinoma: pCR predicted better RFS for patients with HER2+ breast cancer (HR 0.69, 95 per cent c.i. 0.57 to 0.83, P < 0.001, I2 = 0 per cent; 18 studies) (Fig. 4 and Fig. S7).